key: cord-0690515-0q2asds3
authors: Brenner, Benjamin; Ay, Cihan; Le Gal, Grégoire; Carrier, Marc; Muñoz, Andrés J.; Agnelli, Giancarlo; Cavalcanti Rocha, Ana Thereza; Abdel-Razeq, Hikmat; Elalamy, Ismail; Falanga, Anna
title: Venous thromboembolism risk, prophylaxis and management in cancer patients with COVID-19: An unmet medical need
date: 2022-01-10
journal: Thrombosis Update
DOI: 10.1016/j.tru.2022.100098
sha: 53b445784cdf3e16fc30355fd7940d3f98651353
doc_id: 690515
cord_uid: 0q2asds3

Cancer patients exhibit an increased risk of venous thromboembolism (VTE), with VTE being the second leading cause of morbidity and mortality in these patients. The implementation of lockdowns following the COVID-19 pandemic has resulted in decreased mobility and delayed access to care, thus further increasing the susceptibility to VTE. Cancer patients may also be at a higher risk of SARS-CoV-2 infection and have been shown to be more likely to experience severe COVID-19 disease compared to patients without cancer. Given that both cancer and COVID-19 exhibit a hypercoagulable state, stasis of blood flow, and endothelial injury, cancer patients with COVID-19 constitute a vulnerable population with a high risk of thrombosis and bleeding. However, to date there are limited studies evaluating whether cancer patients infected with SARS-CoV-2 have a higher VTE incidence than COVID-19 patients without cancer, how to assess the risk of VTE, prophylaxis and treatment in this special population. Herein, we highlight the urgent need for studies in cancer patients with COVID-19 to ensure appropriate patient care and improve clinical outcomes.

There is a need for studies in cancer patients with COVID-19 to ensure appropriate patient care and improve clinical outcomes Cancer and COVID-19 exhibit a hypercoagulable state, stasis of blood flow, and endothelial injury 1 The mechanisms leading to thrombosis in cancer 2 and COVID-19 3 are distinct, but there are commonalities that may lead to death [4] . To date, several mechanisms have been proposed to explain COVID-19-associated MODS but growing evidence points toward the role of hypercoagulation, and a high prevalence of micro-and macro-circulatory thrombosis has been reported to trigger morbidity and mortality in critically ill COVID-19 patients [5] .

The risk of thromboembolism in COVID-19 has been observed to vary with disease progression, with increased hypercoagulability in more severe COVID-19 cases. Several risk factors seem to be associated with progression into severe forms of COVID-19 including age, gender, and pre-existing comorbidities such as cardiovascular, lung, kidney and central nervous system diseases, diabetes, obesity and cancer [6, 7] . The VTE risk is also significantly higher among patients admitted to the intensive care unit (ICU) versus non-ICU hospitalized patients. 3.5% of ICU and non-ICU patients respectively [8] .

Both cancer and COVID-19 exhibit a hypercoagulable state, stasis of blood flow, and endothelial injury [9] . While the pathophysiological mechanisms leading to thrombosis in cancer patients [10] are distinct from those in COVID-19 patients [11] , there are commonalities and both cancer and COVID-19 increase the risk of VTE. Proinflammatory cytokines, including tumour necrosis factor-α and interleukin 1, are induced by both COVID-19 and cancer and are significant contributors in the development of thrombosis in both clinical scenarios [12] . Given that both cancer and COVID-19 exhibit hypercoagulation and altered haematological parameters, an increased incidence of VTE or bleeding in cancer patients with COVID-19 cannot be discounted. Thus, patients that have both cancer and COVID-19

constitute a unique population that requires special attention for thrombosis risk management.

Only p=0.023) [16] . A worse outcome in patients with haematological malignancies and COVID-19, compared to patients who had either COVID-19 alone or haematological malignancies alone was also reported in an Italian retrospective multi-centre study [17] .

Although several recommendations have been made by international organisations with respect to cancer care [18] during the COVID-19 era and anticoagulation treatment in COVID-19 patients [19] [20] [21] [22] [23] , no international guidelines exist to direct clinicians on anticoagulation use in patients that have both cancer and COVID-19. 

All authors have contributed to the preparation of this manuscript.

Venous thromboembolism and prognosis in cancer

Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants

The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study

Evaluation and Treatment Coronavirus (COVID-19)

Coagulopathy of Coronavirus Disease

Covid-19: risk factors for severe disease and death

Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive

Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost

Similarities and Perspectives on the two C's -Cancer and COVID-19

Mechanism and management of cancer-associated thrombosis

The unique characteristics of COVID-19 coagulopathy

Thrombosis and Hemostasis Issues in Cancer Patients with COVID-19

Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19

Clinical Course of Cancer Patients With COVID-19: A Retrospective Cohort Study

Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

Clinical characteristics and risk factors associated with COVID-19 severity in patients with in Italy: a retrospective, multicentre, cohort study

COVID-19 and cancer care: what do international guidelines say?

Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19 -a Swiss consensus statement by the Working Party Hemostasis

Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum

Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands

Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology

Clinical management of COVID-19

Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology J o u r n a l P r e -p r o o f and Medical Oncology (DGHO)

A minimal common outcome measure set for COVID-19 clinical research

Bleeding in COVID-19 severe pneumonia: The other side of abnormal coagulation pattern?

Andrés J. Muñoz is Head of Cancer & Thrombosis Section of the Spanish Society of Medical Oncology (SEOM) and Coordinator of TESEO-SEOM Registry of cancer-associated thrombosis, and received consulting fees from Sanofi, BMS, Leo Pharma, Pfizer, Astrazeneca. Also received honoraria from Rovi, Bayer, Daichii-Sankyo and travel grant from Roche, Amgen and Merck. Giancarlo Agnelli reports personal fees from Werfen

Boehringer Ingelheim and Sanofi. Hikmat Abdel-Razeq has nothing to report

Anna Falanga is a full professor of Hematology at the University of Milan Bicocca and Director of the Department of

Received honoraria from Werfen

We thank Sai Krishnaveni Chevooru (Sanofi) for medical writing and editorial support. This publication was supported by Sanofi. However, the authors received no payment from Sanofi directly or indirectly (through a third party) related to the development/presentation of this publication.J o u r n a l P r e -p r o o f